Skip to main content
. 2018 Feb 2;9:16. doi: 10.3389/fpsyt.2018.00016

Table 1.

Demographics and clinical characteristics of the participants.

Patients with schizophrenia (mean ± SD) Healthy controls (mean ± SD) Comparison between groups
Sex, n (female/male) 32 (24/8) 32 (21/11) χ2 = 0.674, p = 0.412
Age, years 31.3 ± 9.8 31.9 ± 10.9 t(df = 62) = 0.253, p = 0.801
Handedness 96.7 ± 13.0 97.7 ± 10.8 t(df = 62) = 0.334, p = 0.739
Education, years 13.7 ± 2.2 14.7 ± 2.2 t(df = 62) = 1.822, p = 0.073
Estimated premorbid IQ 98.6 ± 9.4 100.3 ± 8.3 t(df = 62) = 0.744, p = 0.460
Duration of illness, years 9.7 ± 6.8
Chlorpromazine-equivalent dose, mg/day 488.9 ± 315.9
PANSS
Positive 13.8 ± 4.0
Negative 18.1 ± 5.3
General psychopathology 31.6 ± 9.1
Number of words generated 11.9 ± 3.7 14.3 ± 3.8 t(df = 62) = 2.496, p = 0.015
BCIS
Self-reflectiveness 11.2 ± 3.7
Self-certainty 5.3 ± 3.1
SF-36
Physical functioning 46.8 ± 13.7
Role limitations—physical 38.1 ± 15.6
Bodily pain 48.1 ± 12.7
General health 40.6 ± 12.8
Vitality 41.6 ± 12.9
Social functioning 42.9 ± 14.6
Role limitations—emotional 36.1 ± 15.2
Mental health 40.7 ± 12.6

df, degrees of freedom; IQ, intelligence quotient; PANSS, Positive and Negative Symptom Scale; BCIS, Beck Cognitive Insight Scale; SF-36, Medical Outcomes Study 36-item Short-Form Health Survey.